14 results about "Cardiovascular Complication" patented technology

Blood plasma samples are obtained from type 2 diabetes (T2D) patients and a concentration of F2-isoprostanes (F2I) in the sample is quantified. Plasma F2I levels assess oxidative stress levels in the patient and indicate elevated risk of T2D-associated complications including incident clinical fracture, cardiovascular complications, renal disease, etc. in the T2D cohort, independently of other risk factors. Fracture risk in the T2D population is heightened for a given bone mineral density (BMD) and is underestimated by evaluation tools such as Fracture Risk Assessment Tool (FRAX). The patient's BMD T-score can be adjusted based on F2I concentrations, capturing reductions in bone quality as well as quantity that lead to the elevated fracture risk in T2D patients. These diagnostic procedures can be effectively deployed in a patient's course of treatment merely by supplementing an existing blood panel, rather than with a separate blood draw.

The invention relates to the technical field of medical health data processing, in particular to a diabetic cardiovascular complication early warning method and system, and the method comprises the steps: obtaining health data of a to-be-evaluated diabetic patient, encrypting the health data of the to-be-evaluated diabetic patient, and obtaining the encrypted health data; inputting the encrypted health data into a pre-set early warning feature acquisition model to acquire early warning features of cardiovascular complications; and inputting the early warning features of the cardiovascular complications into a pre-set cardiovascular complication scoring model, obtaining a cardiovascular complication score of the to-be-evaluated diabetic patient, and performing early warning according to a pre-set early warning rule. The technical problems that in the prior art, data fusion precision is low, calculation efficiency is poor, and an effective mechanism for ensuring data consistency and safety is lacked are solved.

The invention belongs to the technical field of biomedicine, and particularly discloses a glycated peptide fragment marker for early prediction of cardiovascular complications of peritoneal dialysis patients and application of the glycated peptide fragment marker. According to the invention, 54 glycosylated peptide fragment markers having significant contribution to distinguishing CVD patients from CVD-free patients are screened based on a glmnet machine learning model, and three preferable glycosylated peptide fragment markers SGLSTGWTQLSK (g) LLELTGPK, GEAFTLK (g) ATVLNYLPK and K (g) QHLFVK are further screened according to a target peptide fragment selection standard, a glmnet model importance coefficient mean value and chemical properties of glycosylated peptide fragments. And the marker is verified to have a good prediction level on cardiovascular complications of peritoneal dialysis patients. According to the method, early prediction of cardiovascular complications of peritoneal dialysis patients can be realized, more and better target choices are provided for prediction of the diseases, and the method has good clinical application value.

Provided are use of an IL-1α inhibitor in preparing a medicament for treating leukemia therapy-induced cardiac injury and use of an IL1R1 antagonist in preparing a medicament for treating leukemia therapy-induced cardiac injury. The present disclosure can effectively reduce cardiovascular complications and the occurrence of long-term cardiovascular adverse events in the period of leukemia treatments, thereby helping alleviate the cardiac metabolic dysfunction and cardiac dysfunction after treatment.

The invention discloses a cardiovascular complication risk prediction and dialysis method based on multi-dimensional data, which comprises a dialysate blending device, the dialysate blending device adds a potassium chloride solution into dialysate according to the blood potassium level of a patient to regulate and control the potassium ion concentration of the dialysate, and conveys the potassium ion concentration to a dialysis machine; the prediction and dialysis method comprises the following steps: firstly, collecting multi-dimensional data of a patient, and constructing a cardiovascular complication risk prediction model by utilizing big data analysis and machine learning technologies and combining the multi-dimensional data; predicting the possibility of cardiovascular events caused by blood potassium imbalance of the patient in a future period of time in advance; according to a prediction result, adjusting a dialysate potassium ion concentration strategy of the patient before dialysis; in the later treatment stage, the blood potassium level of the current patient is monitored, regulated and controlled, and individualized treatment is conducted according to the current blood potassium concentration. The potassium ion concentration strategy of the dialysate can be adjusted in advance, preventive treatment is implemented, and the treatment gate is moved forward.

A synergistic combination of agents with a protective effect on vascular endothelial function is disclosed, for use in the treatment and prevention of complications of anticancer therapies.

The invention relates to the technical field of medicaments, and discloses a medicament and a method for relieving inflammatory response of chronic nephropathy by a composition for regulating intestinal flora, the medicament takes'probiotics, prebiotics and postbiotics' as a core, the probiotics contain bifidobacterium lactis and Akk bacteria, the prebiotics are fructo-oligosaccharide-inulin mixture, the postbiotics are butyrin, and the prebiotics and the postbiotics are mixed uniformly. Astragalus polysaccharide / lycium barbarum polysaccharide can be added for synergistic interaction; dosage forms of the enteric capsule, the powder and the oral suspension are divided into enteric capsules, powder and oral suspension, the enteric capsule is suitable for different people groups, inflammation is relieved by repairing intestinal barriers, inhibiting NF-kB channels and optimizing flora, after 12-24 weeks of administration, serum IL-6, TNF-alpha and hs-CRP are reduced by 15%-55%, renal functions and cardiovascular complications are synchronously improved, the enteric capsule is free of kidney toxicity, the adverse reaction rate is smaller than or equal to 5%, and the enteric capsule is suitable for long-term intervention of CKD inflammation.

The invention discloses a pharmaceutical composition for treating obstructive sleep apnea and a preparation method thereof. The pharmaceutical composition and the pharmaceutical preparation provided by the invention can remarkably improve the symptom of obstructive sleep apnea and can remarkably reduce the myocardial infarction area, and a new strategy is provided for treatment of obstructive sleep apnea and cardiovascular complications thereof. Meanwhile, the pharmaceutical composition and the preparation provided by the invention are scientific and clear in formula and mature in preparation process, can realize large-scale production by utilizing conventional equipment and auxiliary materials in the pharmaceutical industry, and have good market prospects and industrialization potential.

This application discloses a predictive model, method, and system for cardiovascular complications in peritoneal dialysis patients based on glycated proteomics and machine learning. This application utilizes techniques such as glycated peptide enrichment, high-throughput glycated proteomics detection, targeted absolute quantification, and machine learning modeling to construct a predictive model suitable for assessing the risk of CVD complications in peritoneal dialysis patients. This model organically integrates glycated peptide biomarkers with clinical indicators, enabling early identification and stratified management of cardiovascular risk in peritoneal dialysis patients, and has good clinical application potential.

The invention belongs to the technical field of biomedicine, and particularly discloses an alpha1-antitrypsin glycated peptide fragment marker for early prediction of cardiovascular complications of peritoneal dialysis patients and application of the alpha1-antitrypsin glycated peptide fragment marker. The alpha1-antitrypsin glycosylated peptide fragment marker is obtained through screening and can be used for early prediction of occurrence of cardiovascular complications of peritoneal dialysis patients, and the sequence of the alpha1-antitrypsin glycosylated peptide fragment marker is ELDRDTV FALVNYIFFK (g) GK (g is a saccharification modification site). The invention further constructs an absolute quantification method of the alpha1-antitrypsin glycated peptide fragment marker and is applied to early prediction of cardiovascular complications of clinical peritoneal dialysis patients. The problem that an existing CVD complication biomarker cannot predict disease occurrence in time is effectively solved, and good clinical application value is achieved.

The invention belongs to the technical field of diagnosis and treatment of diabetic complications, and discloses an auxiliary diagnosis and treatment method for cardiovascular complications of gestational diabetes mellitus, which comprises the following steps: S1, collecting an umbilical vein endothelial cell sample of a gestational diabetes mellitus patient; s2, detecting the expression level of miR-584-5p in the umbilical vein endothelial cell sample and the expression levels of the PTEN gene and the downstream PINK1 protein thereof, and detecting related indexes of mitochondrial autophagy at the same time; s3, in combination with clinical indexes, based on the expression level of miR-584-5p, the expression levels of the PTEN gene and the downstream PINK1 protein thereof and related indexes, evaluating the occurrence risk of the cardiovascular complications of the offspring of the gestational diabetes mellitus patient. The application provides molecular evidence for early discovery of endothelial cell dysfunction, and assists in assessment of cardiovascular complication risk of patients.

The invention discloses a polydopamine modified nifedipine nano-platform and a preparation method and application thereof, the particle size of the polydopamine modified nifedipine nano-platform is 100-300 nm, the polydopamine modified nifedipine nano-platform is hexagonal, the polydopamine modified nifedipine nano-platform is composed of hollow polydopamine nano-particles serving as a carrier and nifedipine loaded on the hollow polydopamine nano-particles, and the hollow polydopamine nano-particles are prepared through a reaction of ZIF-8 and dopamine. According to the present invention, the drug loading capacity and the tumor targeting capacity are excellent, the tumor cells can be targeted through the EPR effect, and the breast cancer cells can be effectively killed; it is clear that nifedipine inhibits breast cancer through a GnRH signal channel for the first time, and new drug selection and drug combination strategies are provided for breast cancer treatment; the anti-tumor and cardiovascular protection effects are considered, and the risk of cardiovascular complications in the treatment of breast cancer patients can be reduced.

The application discloses a kind of polydopamine modified nifedipine nano platform and its preparation method and application, its particle size is 100-300 nm, present hexagon, by as carrier hollow polydopamine nanoparticle and the nifedipine loaded on it constitute, wherein, hollow polydopamine nanoparticle is made by ZIF-8 and dopamine response.The application has excellent drug loading capacity and the targeting ability to tumor, can target tumor cells by EPR effect, effectively kill breast cancer cells;Firstly, it is clear that nifedipine inhibits breast cancer through GnRH signal pathway, provides new drug selection and combined drug strategy for breast cancer treatment;Give consideration to antitumor and cardiovascular protective effect, possibly reduce the risk of cardiovascular complications in breast cancer patient treatment.

The application discloses a dialysis dry body weight evaluation method, system and device based on multi-dimensional features, relates to the technical field of medical health data processing and intelligent monitoring, and comprises the following steps: connecting with an intelligent acquisition device, and automatically acquiring multi-dimensional data packets including exclusive tags generated in the whole dialysis process of a patient; performing multi-feature cross verification on the multi-dimensional data based on the exclusive tags, and performing abnormal data interception and intervention to obtain an effective data set; performing multi-dimensional disintegration and quantitative assignment on the effective data set, and integrating to form a plurality of evaluation dimensions and a plurality of fine evaluation indexes; and the technical key points are as follows: precise archiving of multi-source data is realized by constructing a high-fault-tolerant data claim logic; and objective dry body weight adjustment instructions are output by a big data model based on the archived body weight, blood pressure and blood vessel access auscultation audio, so that the incidence of cardiovascular complications is reduced, a global health weight management closed loop is realized, and the application has a good application prospect.